A Phase III, Multi-centre, Randomized, Rater- and Patient-blind, Placebo- and Active-controlled, Parallel Group Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily (Active Test Treatment), Ambroxol Hydrochloride 30 mg Twice Daily (Active Control Treatment) and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
Latest Information Update: 06 Jan 2023
At a glance
- Drugs Acetylcysteine (Primary) ; Ambroxol
- Indications Acute bronchitis; Bronchiectasis; Chronic bronchitis; Cystic fibrosis; Emphysema; Respiratory tract disorders
- Focus Registrational; Therapeutic Use
- Sponsors Zambon SpA
- 22 Feb 2021 Status changed from recruiting to completed.
- 20 May 2020 Planned End Date changed from 30 Apr 2020 to 24 Apr 2021.
- 20 May 2020 Planned primary completion date changed from 30 Apr 2020 to 24 Apr 2021.